IRVINE, CALIF. – May 8, 2025 – BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), an independent corporate climate action organization that enables companies worldwide to play their part in combating the climate crisis. This milestone reinforces BioDuro’s commitment to sustainability and underscores its dedication to environmental stewardship and corporate social responsibility.
By validating its targets, BioDuro has committed to making a 42% absolute reduction in both Scope 1 (direct GHG emissions from owned/controlled sources) and Scope 2 (indirect GHG emissions from purchased electricity, steam, heating, and cooling) by 2030 against a 2023 baseline, with parallel monitoring and reduction of Scope 3 (value chain GHG emissions including upstream/downstream activities). To achieve these targets, BioDuro will implement a series of measures including establishing company-wide energy performance standards, upgrading equipment to be more energy-efficient, increasing its use of renewable energy, and promoting supply chain decarbonization.
“In setting science-based targets that are independently validated by SBTi, we at BioDuro are demonstrating our commitment to climate action and our ambitions for decarbonization," said Dr. Armin Spura, CEO of BioDuro. “We will deliver these targets by empowering our R&D and production teams to pioneer eco-friendly solutions, while ensuring operational teams implement best-in-class sustainability practices. We encourage industry partners to join us in pursuing green development initiatives for a sustainable future.”
About BioDuro
BioDuro, an Advent International portfolio company, is a CRDMO with a 29-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, and over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product.
Media Enquiries
Christina Coby, Marketing Manager, BioDuro
Email: christina.coby@bioduro.com
Mobile: +1 (619) 414 7409
For more information, please visit https://www.bioduro.com
Home